A 28-day clinical trial with 31 subjects compared a 0.1 % pterostilbene skincare emulsion to a control using a double-blind, split-face design. Advanced tools and self-assessments showed the pterostilbene emulsion significantly improved skin elasticity, reduced wrinkles, and increased epidermis thickness and collagen intensity. It outperformed the control in multiple metrics (p < 0.05) and gained higher subject satisfaction, highlighting its potent anti-aging effects and value in cosmetics.

A group at Niigata University succeeded in the treatment of a brainstem glioma patient with a rare IDH2 mutation. Brainstem gliomas with H3K27M mutation are usually refractory to temozolomide. However, in adult brainstem glioma patients, rare IDH1/2 mutations can be found. Treatment response can be expected in these patients. Therefore, screening for 2-hydroxyglutarate accumulation using magnetic resonance spectroscopy and safe surgical biopsy are necessary to determine the proper treatment.

In a landmark move to bridge global medical innovation, LabMed Discovery has opened its first international office at the University of Rome Tor Vergata. This strategic partnership, formalized with a signing ceremony attended by Chinese and Italian delegates, promises to accelerate collaborative research and journal visibility worldwide. The office underscores China’s commitment to fostering cross-border scientific dialogue and journal excellence.

Radiopharmaceuticals have become indispensable tools in precision medicine, revolutionizing diagnostic imaging and targeted therapeutic strategies. This manuscript provides an overview of advancements globally and in China, focusing on the classification and clinical applications of radiopharmaceuticals, particularly in oncology and neurology. Recent progress includes PET/SPECT diagnostic agents and therapeutic radionuclides that provide precise treatment while limiting damage to healthy tissues. Emerging technologies, such as artificial intelligence, novel ligands, advanced radionuclides, and combination therapies, present promising avenues to further enhance the efficacy and accessibility of the field. Despite these achievements, challenges remain in production, regulatory, and costs, underscoring the need for ongoing innovation and international collaboration to fully realize the potential of radiopharmaceuticals in personalized healthcare and optimize patient outcomes.